Phase 2 trials demonstrated 24.2% average weight loss at 48 weeks, with the 12mg dose producing up to 27.3% reduction in some participants
Weigel, C., Kiener, C., Meier, N., Schmid, P., Rauh, M., Rascher, W., and Knerr, I
This makes it uniquely effective for: Visceral fat reduction (glucagon is specifically active on abdominal fat stores) Resting metabolic rate increase (glucagon is thermogenic it raises your metabolic baseline) Food noise suppression (GLP-1 component dampens reward-driven eating) Satiety signaling (GIP + GLP-1 extend fullness after meals) Because of this third mechanism, the clinical trial results for Retatrutide are notably better than other approved GLP-1s for body weight reduction
Optic Labs is not a compounding pharmacy or manufacturing facility as defined under the Therapeutic Goods Act 1989, and is not a registered provider of scheduled medicines or therapeutic goods